Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Optimizing dosing of oncology drugs.

Minasian L, Rosen O, Auclair D, Rahman A, Pazdur R, Schilsky RL.

Clin Pharmacol Ther. 2014 Nov;96(5):572-9. doi: 10.1038/clpt.2014.153. Epub 2014 Aug 8. Review.

PMID:
25105705
2.

Dose-toxicity models in oncology.

Adamina M, Joerger M.

Expert Opin Drug Metab Toxicol. 2011 Feb;7(2):201-11. doi: 10.1517/17425255.2011.543674. Review.

PMID:
21241201
3.

Optimizing drug development of anti-cancer drugs in children using modelling and simulation.

van Hasselt JG, van Eijkelenburg NK, Beijnen JH, Schellens JH, Huitema AD.

Br J Clin Pharmacol. 2013 Jul;76(1):30-47. doi: 10.1111/bcp.12062. Review.

4.

Improving adherence and clinical outcomes through an HIV pharmacist's interventions.

Ma A, Chen DM, Chau FM, Saberi P.

AIDS Care. 2010 Oct;22(10):1189-94. doi: 10.1080/09540121003668102.

PMID:
20640958
5.

[Role of individualized dosing in oncology: are we there yet?].

Joerger M.

Praxis (Bern 1994). 2013 Dec 31;103(1):33-9. doi: 10.1024/1661-8157/a001516. Review. German.

PMID:
24393821
6.

Evaluation of fixed dosing of new anticancer agents in phase I studies.

Levêque D.

Anticancer Res. 2008 Sep-Oct;28(5B):3075-7.

7.

Dose calculation of anticancer drugs.

Gao B, Klumpen HJ, Gurney H.

Expert Opin Drug Metab Toxicol. 2008 Oct;4(10):1307-19. doi: 10.1517/17425255.4.10.1307 . Review.

PMID:
18798700
8.

[Anticancer drug dose individualisation: from body surface area to physiology].

Pétain A, Chatelut E.

Bull Cancer. 2008 Oct;95(10):895-901. doi: 10.1684/bdc.2008.0720. French.

PMID:
19004718
9.

Practical guidelines for dose individualization of anticancer targeted drugs.

Sáez MI, Quero C, Trigo JM, Muros B, Alba E.

Clin Transl Oncol. 2012 Nov;14(11):812-9. doi: 10.1007/s12094-012-0932-x. Epub 2012 Oct 12. Review.

PMID:
23065600
10.

Phase I studies of weekly administration of cytotoxic agents: implications of a mathematical model.

McClish DK, Roberts JD.

Invest New Drugs. 2003 Aug;21(3):299-308.

PMID:
14578680
11.

Interventions to promote adherence with oral agents.

Schneider SM, Hess K, Gosselin T.

Semin Oncol Nurs. 2011 May;27(2):133-41. doi: 10.1016/j.soncn.2011.02.005. Review.

12.

Adherence to oral cancer therapies: nursing interventions.

Winkeljohn D.

Clin J Oncol Nurs. 2010 Aug;14(4):461-6. doi: 10.1188/10.CJON.461-466.

PMID:
20682501
13.

Determining the optimal dose in the development of anticancer agents.

Mathijssen RH, Sparreboom A, Verweij J.

Nat Rev Clin Oncol. 2014 May;11(5):272-81. doi: 10.1038/nrclinonc.2014.40. Epub 2014 Mar 25. Review.

PMID:
24663127
14.

Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse.

Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, Wheler J, Kurzrock R.

Clin Cancer Res. 2010 Feb 15;16(4):1289-97. doi: 10.1158/1078-0432.CCR-09-2684. Epub 2010 Feb 9.

15.

Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model.

Iliadis A, Barbolosi D.

Comput Biomed Res. 2000 Jun;33(3):211-26.

PMID:
10860586
16.

New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.

Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G.

Clin Cancer Res. 2005 Aug 1;11(15):5342-6.

17.
18.

Body surface area as a determinant of pharmacokinetics and drug dosing.

Sawyer M, Ratain MJ.

Invest New Drugs. 2001 May;19(2):171-7. Review.

PMID:
11392451
19.

[Pharmacokinetics and therapeutic drug monitoring of anticancer agents].

Marquet P, Rousseau A.

Bull Cancer. 2008 Oct;95(10):903-9. doi: 10.1684/bdc.2008.0725. French.

PMID:
19004719
20.

Chemotherapy individualization.

Veal GJ, Coulthard SA, Boddy AV.

Invest New Drugs. 2003 May;21(2):149-56. Review.

PMID:
12889736
Items per page

Supplemental Content

Write to the Help Desk